Curis Lifesciences IPO is a book-built issue with an entirely fresh issue of 20,50,000 Equity Shares at a face value of ₹10, aggregating to ₹27.52 Cr. The bidding period for the IPO subscription opens on 7 November 2025 and closes on 11 November 2025.
The Curis Lifesciences IPO allotment is tentatively scheduled for 12 November 2025. The Curis Lifesciences IPO is to be listed on NSE SME as of 14 November 2025.
The price band for Curis Lifesciences IPO is set at ₹120.00 to ₹128.00 per share. The lot size for each IPO application is 1,000 shares with a minimum investment of ₹2,56,000, that is 2 lots per application, at the upper band, for the retail investors. The lot size for HNIs is 3 lots of 3,000 shares, which is ₹3,84,000.
Curis Lifesciences IPO Details
To know more about Curis Lifesciences IPO Share price, price band, issue and sale type, and fresh issue, check out Curis Lifesciences IPO details in India:
| IPO Open Date | 7 November 2025 |
| Close Date | 11 November 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹120.00 to ₹128.00 per share |
| Issue Price | Undisclosed |
| IPO Lot Size | 1,000 shares |
| Sale Type | Fresh capital |
| Offer for Sale | NA |
| Fresh Issue | 20,50,000 Equity Shares |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size (₹ Cr) | ₹27.52 Cr |
| Reserved for Market Maker | 1,08,000 shares up to ₹1.38 Cr |
| Net Offered to Public | 20,42,000 shares up to ₹26.14 Cr |
| Minimum Investment(₹) | ₹2,56,000 (2 lots) |
| Retail Discount | NA |
Curis Lifesciences IPO Timeline
The Curis Lifesciences IPO timeline, including opening date, closing date, and listing date:
| IPO Open Date | 7 November 2025 |
| IPO Closing Date | 11 November 2025 |
| Tentative Allotment | 12 November 2025 |
| Initiation of Refunds | 13 November 2025 |
| Credit of Shares to demat | 13 November 2025 |
| Tentative Listing Date | 14 November 2025 |
| Cut-off Time for UPI Mandate Confirmation | 11 November 2025, 5 PM |
Curis Lifesciences IPO Grey Market Premium (GMP Today)
The Curis Lifesciences IPO GMP today is at ₹0. An increase in the GMP of an IPO indicates positive sentiment among investors and the market before the listing.
| Date | GMP (₹) | Estimated Listing Price | Estimated Listing Gain | Trend |
| 4 November 2025 | ₹0 | ₹128 (0.00%) | ₹0 | – |
| 3 November 2025 | ₹0 | ₹128 (0.00%) | ₹0 | – |
The Grey Market Premium (GMP) values are based on real-time market fluctuations for the demand of an IPO, subscription level, and market mood.
What is the Percentage of Curis Lifesciences IPO GMP?
The Grey Market Premium (GMP) for Curis Lifesciences IPO is currently at ₹0, which means the GMP percentage is 0.00%. The estimated listing price is ₹128, which matches the IPO price, as on 4 November 2025.
Curis Lifesciences IPO Reservation
The Curis Lifesciences IPO comprises the following reservations made for market makers, QIBs, retail investors, and NIIs.
| Category | % of Shares Offered | Shares offered |
| Anchor Investors | 22.10 | 6,10,000 |
| Market Maker | 5.02 | 1,08,000 |
| QIBs | 47.35 | 10,18,000 |
| Retail Investors | 33.30 | 7,16,000 |
| NII (HNI) | 14.33 | 3,08,000 |
| Total Shares Offered | 100% | 21,50,000 |
Curis Lifesciences Key Performance Indicator
Overview of KPIs and qualitative factors of Curis Lifesciences for the past three years (2022 to 2024).
| KPIs | 2024 | 2023 | 2022 |
| ROE (%) | 145.20 | 8322.25 | (42.52) |
| ROCE (%) | 34.89 | 20.38 | 17.00 |
| Debt to Equity Ratio (in times) | 2.86 | 17.08 | (19.50) |
| RoNW (%) | 84.12 | 195.28 | (54.50) |
| PAT Margin (%) | 14.13 | 5.23 | 2.07 |
| EBITDA Margin (%) | 23.65 | 9.18 | 15.07 |
| Price Book Value | – | – | – |
Curis Lifesciences Financials
| Aspect | 2024 (₹ lakh) | 2023 (₹ lakh) | 2022 (₹ lakh) |
| Revenue | 3,588.91 | 3,638.70 | 2,376.19 |
| Total Asset | 3,381.58 | 2,966.75 | 2,739.86 |
| Profit | 502.51 | 185.17 | 49.23 |
Curis Lifesciences IPO Lot Size
This table breaks down the Curis Lifesciences IPO lot size and requirement of minimum investment from each investor category:
| Application | Lot Size | Shares | Amount(in ₹) |
| Individual investors (Retail) (Min) | 2 | 2,000 | 2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | 2,56,000 |
| S-HNI (Min) | 3 | 3,000 | 3,84,000 |
| S-HNI (Max) | 7 | 7,000 | 8,96,000 |
| B-HNI (Min) | 8 | 8,000 | 10,24,000 |
Curis Lifesciences Promoter Holding
Mr. Dharmesh Dashrathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala, and Mr. Jaimik Mansukhbhai Patel are the promoters of Curis Lifesciences, and their pre-issue and post-issue holdings are as stated below:
| Pre-Issue Promoter Holding | 92.68% |
| Post-Issue Promoter Holding | 68.03% |
Curis Lifesciences IPO Anchor Investors Details
This table showcases the funds raised from the anchor investors through the Curis Lifesciences IPO.
| Bid Date | 6 November 2025 |
| Shares Offered | 6,10,000 shares |
| Anchor Portion Size (In Cr.) | 7.81 Cr |
| Anchor lock-in period end date for 50% shares (30 Days) | 12 December 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | 10 February 2026 |
Curis Lifesciences IPO Prospectus
Check out the official documents filed with SEBI for more details on the Curis Lifesciences IPO.
| DRHP (Doc) | |
| RHP (Doc) | Undisclosed |
| IPO Final Prospectus | Undisclosed |
| Anchor Investors | Undisclosed |
About Curis Lifesciences
| Founded in | 2 June 2010 |
| Chairman and Managing Director (CMD) | Mr. Dharmesh Dasharathbhai Patel |
| Parent Organisation | NA |
| Services Provided | Loan license and contract manufacturing, and export and manufacturing its brand products. |
| Book running lead manager | Finaax Capital Advisors Private Limited |
| Registrar of the issue | MUFG Intime India Private Limited |
Objectives of the Curis Lifesciences
The Curis Lifesciences IPO details of the use of net proceeds from the fresh issue are described below:
| Fund Utilisation | Amount (in ₹ lakh) |
| Capital Expenditure towards Upgradation Manufacturing Facilities | 244.27 |
| Capital Expenditure for Construction of Storage Facility | 361.99 |
| Payment of Outstanding Loans | 259.80 |
| Product Registrations in other countries | 260.88 |
| General Corporate Purposes | Undisclosed |
| Working Capital Requirements | 1,125.00 |
Strength Of Curis Lifesciences
- Experienced Team, Steady Growth: The company’s promoters lead strategic decisions and daily operations, which drive growth, with over 56 years of combined industry experience.
- Diverse Product Lineup: The company manufactures over 900 approved pharmaceutical products across multiple therapeutic categories to meet healthcare needs in the global markets.
- Global-Grade Manufacturing Flex: The company’s WHO-GMP certified plant in Sanand meets the international quality standards and is approved by several global health authorities.
- Scale with Smart Efficiency: The company’s customer-focused model supports large-scale, flexible production while maintaining consistent quality and cost-effectiveness.
Risk of Curis Lifesciences
- Approval and Compliance Risk: The company’s operations rely on regulatory approvals and license renewals, and any sort of delay or cancellation could disrupt operations and affect growth.
- Revenue on Repeat: The company’s significant portion of the revenue comes from a limited number of products, customers, and regions. The loss of any key customer or a decline in demand for major products could impact financial performance.
- Operational and Manufacturing Risk: The business depends on a consistent supply of raw materials, utilities. Any production or logistics disruptions may result in delays, cost imbalances, or reputational harm.
- Competitive and Financial Risk: The pharmaceutical industry is highly competitive. So, competition, pricing challenges, and reliance on borrowed funds could impact profitability, limiting future expansion.
Curis Lifesciences IPO Review
Curis Lifesciences IPO has shown strong operational growth, supported by experienced promoters, a wide product range, and global-standard manufacturing. Its financial performance reflects improving margins and efficient capacity utilisation.
However, risks like revenue concentration and industrial competition remain. Overall, the Curis Lifesciences IPO appears suitable for investors seeking a growing pharmaceutical player with long-term potential.
Other Recent IPO List
Check out more ongoing and upcoming IPOs in India, 2025:
| Finbud Financial Services IPO | Orkla India IPO |
| Lenskart Solutions IPO | Jayesh Logistics IPO |
| Studds Accessories Ltd. IPO | Game Changers Texfab IPO |
| Safecure IPO | Shreeji Global FMCG |
Curis Lifesciences IPO FAQ‘s
The Curis Lifesciences IPO is an SME book-built issue worth ₹27.52 crore, comprising an entirely fresh issue of 20,50,000 equity shares to be listed on the NSE SME platform on 14 November 2025.
Investors can apply online through ASBA-enabled bank accounts or UPI through brokers and trading platforms that offer SME IPO applications.
Curis Lifesciences Ltd. reflects a steady financial growth, strong promoter experience, and expanding operations. However, concentration and competition risks remain, making the IPO suitable for investors with a medium to long-term view.
The Grey Market Premium (GMP) for the Curis Lifesciences IPO is currently ₹0, which suggests a neutral market mood. The listing gains, if any, will depend on overall investor response and market conditions during the listing period.
The Curis Lifesciences IPO opens for subscription on 7 November 2025 and closes on 11 November 2025.
The lot size for Curis Lifesciences IPO is 1,000 shares, with a minimum investment of ₹2,56,000 for retail investors at the upper price band.
The Curis Lifesciences IPO allotment is expected to be finalised on 12 November 2025, with refunds and share credits processed by 13 November 2025.
The Curis Lifesciences IPO is scheduled to be listed on the NSE SME platform on 14 November 2025.
